This document provides an overview of acute kidney injury (AKI). It defines AKI and notes its worldwide epidemiology. The main causes of AKI are discussed as pre-renal, renal, and post-renal. The pathophysiology of each type is explained. Clinical presentation depends on the cause but may include elevated creatinine and reduced urine output. Staging of AKI is outlined using KDIGO criteria. Investigations and management aim to identify and treat the underlying cause while maintaining fluid and electrolyte balance. Complications include fluid overload and metabolic disturbances. Prognosis depends on severity and comorbidities.
This presentation describes the Acute kidney injury (AKI), formerly known as Acute renal failure (ARF). It offers core insights on its classification, etiology, signs, symptoms, diagnosis, management as well as its prognosis.
This presentation describes the Acute kidney injury (AKI), formerly known as Acute renal failure (ARF). It offers core insights on its classification, etiology, signs, symptoms, diagnosis, management as well as its prognosis.
biology of evil, basic understanding of the neuropsychological basis of evilmusayansa
gives a biological understanding of the evil side of mankind.
trying to lay down the neuropsychological basis of evil.
fun to read and easy to understand.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
3. DEFINITION
• AKI refers to the sudden and often reversible loss of renal
function, which develops over days or weeks and is often
accompanied by a reduction in urine volume.
OR
• The abrupt decrease in kidney function, resulting in the
retention of urea and other nitrogenous waste products and in
the dysregulation of extracellular volume and electrolytes.
4. EPIDEMIOLOGY
•Estimates suggest that 13.3 million people worldwide are
affected by AKI annually, 85% of whom live in developing
countries.
•Further it is estimated that up to 1.7 million deaths occur
each year from AKI.
•Approximately 7% of all hospitalized patients and 20% of
acutely ill patients develop AKI.
5. CONTN
• In uncomplicated AKI, mortality is low, however when it is
associated with sepsis and multiple organ failure mortality is 50%–
70% and the outcome is usually determined by the severity of the
underlying disorder and other complications, rather than by kidney
injury itself
• Older patients are at higher risk of developing AKI and have a worse
outcome
• In Uganda, prevalence of AKI was 45.3% with 21.5% of children
having unresolved AKI at 24hours. AKI was more common in
Eastern Uganda (Ruth Namazzi et al, 2022)
10. PATHOPHYSIOLOGY
• Pre-renal; when perfusion to the kidney is reduced
• Renal; when the primary insult affects the kidney itself
• Post-renal; when there is obstruction to urine flow at any point from
the tubule to the urethra.
11. PRE-RENAL
• Pre-renal AKI results from a reduction in renal perfusion, typically due to a
reduction in systemic blood pressure.
• The drop in renal perfusion activates the renin–angiotensin–aldosterone
system, which promotes sodium retention in the kidney and systemic
vasoconstriction in order to restore blood pressure.
• Angiotensin also preferentially constricts the glomerular efferent arteriole,
while prostaglandins are released locally to vasodilate the afferent arteriole.
• The combined effect increases glomerular pressure to maintain GFR,
however if the blood pressure is very low, autoregulation fails and the GFR
falls.
• Importantly, in pre-renal AKI, the kidney is not damaged, therefore GFR can
improve rapidly if the renal perfusion is restored.
12.
13. RENAL
• If the drop in renal perfusion is severe or sustained, pre-renal AKI may
progress to renal AKI as ischaemic injury causes ATN, the most extreme
example being with renal arterial or venous occlusion.
• Dead tubular cells may also be shed into the tubular lumen, leading to
tubular obstruction.
• While ischaemia is the most common cause of ATN in hospital, it may also
be caused by toxins and nephrotoxic drugs.
• Drugs can also cause allergic interstitial nephritis.
• The other common ‘renal’ cause of AKI is glomerulonephritis, in which there
is direct inflammatory damage to the glomeruli.
• COVID-19 infection is also associated with AKI in a significant proportion of
patients.
14. POST-RENAL
• Post-renal AKI occurs as the result of obstruction to the renal tract.
• This leads to elevation of intraluminal ureteral pressure transmitted to the
nephrons, with a subsequent fall in GFR.
• The obstruction needs to be bilateral to cause renal failure, therefore it is
unusual for renal stones to cause AKI, while obstruction of the bladder outlet
is a much more common cause.
• If the obstruction is not relieved, the low GFR is maintained by a drop in renal
perfusion via thromboxane A2 and angiotensin II.
• This leads to chronic renal injury over several weeks.
• If obstruction is reversed, the extent of recovery of renal function is
dependent on the duration of obstruction and the pre-morbid GFR
15. CLINICAL FEATURES
• Clinical features of AKI include short duration of symptoms, and an
absence of markers of CKD such as anemia, elevated PTH and small
kidneys observed on imaging.
16. PRE-RENAL
• Tachycardia
• Postural hypotension.
• Signs of poor peripheral perfusion, such as cold peripheries and delayed capillary
return.
• Weight loss
• Warm peripheries in the presence of hypotension may indicate sepsis
• Signs of dehydration
• Crush injuries, burns, abdominal surgeries
• Volume depletion (vomiting, diarrhea, burns, hemorrhage)
• Sepsis, Cardiac disease, Liver disease
• Drugs History (diuretics, ACE inhibitors, ARBs, NSAIDs, calcineurin inhibitors,
iodinated contrast)
17. RENAL
• Patients with glomerulonephritis demonstrate haematuria and proteinuria, and
may have clinical manifestations of an underlying disease, such as SLE or systemic
vasculitis.
• Drug history for example PPIs, NSAIDs and many antibiotics.
• Vascular disease is included here as diseases of the large and small renal vessels
typically present with hypertension and volume expansion, in contrast to the
volume depletion observed in pre-renal failure.
POST-RENAL
• Distended bladder
• DRE; Prostate
• Pelvic mass
18. CRITERIA AND STAGING
KDIGO ( KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES)
The KDIGO guidelines define AKI as follows:
• Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within
48 hours, or
• Increase in serum creatinine to ≥1.5 times baseline, which is known or
presumed to have occurred within the prior seven days, or
• Urine volume <0.5 mL/kg/hour for six hours
19.
20.
21.
22.
23. STAGING OF AKI (KDIGO)
• Stage 1 – Increase in serum creatinine to 1.5 to 1.9 times
baseline, or increase in serum creatinine by ≥0.3 mg/dL (≥26.5
micromol/L), or reduction in urine output to <0.5 mL/kg/hour for 6 to 12
hours.
• Stage 2 – Increase in serum creatinine to 2.0 to 2.9 times
baseline, or reduction in urine output to <0.5 mL/kg/hour for ≥12 hours.
• Stage 3 – Increase in serum creatinine to 3.0 times
baseline, or increase in serum creatinine to ≥4.0 mg/dL (≥353.6
micromol/L), or reduction in urine output to <0.3 mL/kg/hour for ≥24
hours, or anuria for ≥12 hours, or the initiation of kidney replacement
therapy, or, in patients <18 years, decrease in estimated glomerular
filtration rate (eGFR) to <35 mL/min/1.73 m2
24. INVESTIGATIONS
• Serum Electrolytes
• Urinalysis: proteinuria, hematuria, red cell casts, white blood cell casts
• BUN: creatinine ratio
• CBC
• Viral hepatitis screen, HIV, Complement levels, ANA, ASO
• Fractional excretion of sodium
• Serum urate
• Renal ultrasound scan: to screen for urinary tract obstruction,
pyelonephritis.
• Doppler renal USS
• CT angiography
• Renal biopsy
25. MANAGEMENT
• History taking
• Physical examination
• Investigations
• Treatment
Primary goals of treatment
• Maintenance of volume homeostasis
• Correction of biochemical abnormalities.
26. TREATMENT
• Optimization of volume status
• Identify and treat the etiology of AKI
• Treatment of reversible causes e.g. hypotension, volume depletion, urinary
tract obstruction.
• Remove any active insults to minimize new injury.
• Identify and treat the complications that may require KRT.
27. TREATMENT
• Assess fluid status
-If hypovolemic: Fluid challenge.
-If euvolemic, match fluid intake to urine output plus an additional
500mL/24hrs to cover insensible losses.
-If fluid-overloaded, prescribe diuretics like furosemide, if the response is
unsatisfactory, dialysis may be required
• Treat underlying cause
• Discontinue potentially nephrotoxic drugs and reduce doses of therapeutic
drugs according to level of renal function
• Ensure adequate nutritional support
28. CONTN
• If K+>6.5mmol/L and ECG changes of hyperkalemia are present:
Administer calcium gluconate to stabilize myocardium
Decrease intake of potassium in diet.
Lower potassium by oral potassium exchange resin to prevent potassium absorption
Administering intravenous glucose/insulin, sodium bicarbonate, and beta agonists to
move potassium intracellularly.
• These are holding measures until a definitive method of removing potassium is achieved
(restoration of renal function or dialysis).
• Screen for intercurrent infections and treat promptly if present
• Vasodilators??
29. INDICATIONS FOR URGENT KRT/RRT
• Fluid overload e.g. Pulmonary edema
• Hyperkalemia >6.5mEq/L or associated with signs and symptoms
e.g. cardiac, muscle weakness. Or hyperkalemia >5.5mEq/L if
there is ongoing tissue breakdown e.g. rhabdomyolysis.
• Signs of uremia e.g. pericarditis, mental status change.
• Severe metabolic acidosis pH>7.1 with hypervolemia.
• Acute poisoning e.g. methanol, ethylene glycol, lithium.
30. AKI IN OLD AGE
• Physiological change: Nephrons decline in number with age and average GFR
falls progressively, so many older patients will have established CKD and less
functional reserve. Small acute declines in renal function may therefore have a
significant impact.
• Creatinine: As muscle mass falls with age, less creatinine is produced each day.
Serum creatinine can therefore underestimate the severity of renal failure.
• Renal tubular function: Declines with age, leading to loss of urinary
• concentrating ability.
• Drugs: Increased drug prescription in older people (diuretics, ACE inhibitors
and NSAIDs) may contribute to the risk of AKI.
• Causes: infection, renal vascular disease, prostatic obstruction, myeloma and
severe cardiac dysfunction are common.
• Mortality: rises with age, primarily because of comorbid conditions.
31. COMPLICATIONS OF AKI
• Volume overload recognized by Pulmonary edema, HTN,
raised JVP
• Electrolyte disturbances
• Metabolic acidosis
• Neurological complications
• Chronic kidney disease